Goldman initiated coverage on ICON plc with a new price target
$ICLR
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Goldman initiated coverage of ICON plc with a rating of Buy and set a new price target of $370.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/29/2025 | $150.00 | Overweight → Neutral | Analyst |
| 4/14/2025 | $157.00 | Buy → Hold | TD Cowen |
| 4/10/2025 | $165.00 | Overweight → Equal Weight | Barclays |
| 3/21/2025 | $250.00 → $200.00 | Buy → Neutral | Goldman |
| 1/7/2025 | $263.00 | Outperform | RBC Capital Mkts |
| 10/24/2024 | $340.00 | Outperform → Neutral | Robert W. Baird |
| 10/14/2024 | Neutral | Redburn Atlantic | |
| 9/18/2024 | $379.00 | Outperform | Leerink Partners |